Alkem Laboratories reduces the price of Cefuroxime ZOCEF by 35 percent - Video
Overview
One of the leaders in Antibiotics, Alkem Laboratories, have recently announced the reduction in the price of its popular broad-spectrum antibiotic ZOCEF and its three stock keeping units.
To make this versatile antibiotic affordable to the masses for treating various infections, Alkem the No. 1 company in Anti-infectives & Cephalosporin has reduced the prices of its various SKUs by 35%. Cefuroxime is the only Cephalosporin available in Oral & Injectable form.
ZOCEF contains 2nd generation Cephalosporin - Cefuroxime and is recommended in the effective treatment of Surgical Antimicrobial Prophylaxis, Urinary Tract Infections, Upper Respiratory Tract Infections, Bronchitis, Pneumonia, Sinusitis, Tonsillopharyngitis, Acute Otitis Media, Bone & Joint Infections.
Cefuroxime 500 tablets, previously priced at Rs 810 will now be available at just Rs 525. Similarly, price of Cefuroxime sodium injection 1.5g has been reduced from Rs 407.50 per vial to just Rs 265 per vial.
Cefuroxime Axetil oral suspension which was earlier costing Rs 230 will now be available at a cost of just Rs 155 per bottle.
The move comes after government's decision to include Cefuroxime tablets and injections in the National List of Essential Medicine 2022. With this step of price reduction, Alkem laboratories becomes the 1st pharmaceutical company to make Cefuroxime more affordable for every Indian patient.
Cefuroxime is an effective, safe and now affordable 2nd generation cephalosporin antibiotic that shows antibacterial activity against several gram-positive and gram-negative bacteria. Studies have validated its potential to improve patient compliance and also to reduce the rate of clinical failure and the emergence of resistant strains.
Maintaining its global quality standards with Pure Amorphous Cefuroxime & Zero Touch Technology, the medicine is available under the brand name ZOCEF and is available across 6 continents and 14 countries worldwide.
References
1. Wani, F.A.; Bandy, A.; Alenzi, M.J.S.; Alzarea, A.I.; Alanazi, A.S.; Sayeed, M.U.; Thirunavukkarasu, A.; Tantry, B.; Dar, M. Resistance Patterns of Gram-Negative Bacteria Recovered from Clinical Specimens of Intensive Care Patients. Microorganisms 2021, 9, 2246. https://doi.org/10.3390/microorganisms9112246.
2. Scott LJ, Ormrod D, Goa KL. Cefuroxime axetil: an updated review of its use in the management of bacterial infections. Drugs. 2001;61(10):1455-500. doi: 10.2165/00003495-200161100-00008
3. Badhwar VR, Ganapathy S, Prabhudesai PP, Tulara NK, Varaiya AY, Vyas D. A Relook of Cefuroxime in Community Infections: An Option Still Beneficial. J Assoc Physicians India. 2016 Jul;64(7):95-101.
4. Cefuroxime Injection IV 250 mg , 750 mg & 1.5 g Zocef Injection. Alkem Laboratories Ltd. 02/02/2018.
5. Cefuroxime axetil 250, 500 mg Zocef Tablets. Alkem Laboratories Ltd. 02/02/2018.
Disclaimer: This post has been published under MD Brand Connect Initiative and is sponsored by Alkem Laboratories Limited.
Speakers
